HPV vaccine: Cervarix
HPV vaccine: Cervarix
复制标题
DOI：
10.1517/14712591003601944
复制
发表时间：
2010-03-01
影响因子：
4.6
通讯作者：
Szarewski, Anne
中科院分区：
文献类型：
--
作者：
Szarewski, Anne
领域的重要性。宫颈癌是全世界发病和死亡的主要原因，在相对年轻的女性中很常见。宫颈筛查计划虽然如果实施得当会取得成功，但实施起来很困难且昂贵，而且只能提供二级而非一级预防。人乳头瘤病毒 (HPV) 是宫颈癌的主要原因，接种疫苗是向前迈出的重要一步。本综述涵盖的领域。 GSK HPV 疫苗 Cervarix 的数据经过审查，并置于 HPV 疫苗接种的整体背景下。使用 PubMed 列出的出版物和官方产品网站进行了文献综述。读者将获得什么：读者将了解 HPV 疫苗接种所涉及的问题和迄今为止的数据。重要信息：Cervarix 已被证明对与 HPV-16 和 HPV-18 相关的疾病具有高效能。其抗体反应曲线使人们对免疫持续时间持乐观态度。事实上，它是一种类似病毒的颗粒，而不是活病毒疫苗，这一事实在安全性方面令人放心，迄今为止所获得的疫苗制剂的相当广泛的安全数据也是如此。针对致癌性非疫苗 HPV 类型（尤其是 HPV-45）的交叉保护对于预防宫颈腺癌可能很重要，而目前筛查还不能很好地预防宫颈腺癌。
Importance of the field. Cervical cancer is a major cause of morbidity and mortality worldwide and is common in relatively young women. Cervical screening programs, while successful if properly carried out, are difficult and expensive to implement, and offer secondary, not primary prevention. Vaccination against the human papillomavirus (HPV), which is the major cause of cervical cancer, is a significant step forward.Areas covered in this review. The data on Cervarix, the GSK HPV vaccine, are reviewed and placed in the context of HPV vaccination as a whole. A literature review using PubMed listed publications and official product websites has been carried out.What the reader will gain: The reader will gain an understanding of the issues involved in HPV vaccination and of the data to date.Take home message: Cervarix has been shown to have high efficacy against disease associated with both HPV-16 and HPV-18. Its antibody response profile allows for optimism regarding the duration of immunity. The fact that it is a virus-like particle, rather than a live-virus vaccine, is reassuring regarding safety, as are the reasonably extensive safety data for the vaccine preparation so far accrued. Cross protection against oncogenic non-vaccine HPV types, in particular HPV-45, may be important in the prevention of cervical adenocarcinoma, which is currently not well served by screening.